The news of JMP Securities raising the price target for ACADIA Pharmaceuticals from $31 to $39 while maintaining a Market Outperform rating is likely to have a positive impact on the company's stock in the short term. This is because such an upgrade usually signals the analyst's increased confidence in the company's future performance, which can influence investors to buy the stock, thereby driving up its price.